{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-097738","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.404282+00:00","generated_at":"2026-06-07T09:16:24.414725+00:00","sec_items":["1.01","3.02","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Onconetix acquires Proteomedix AG in $75M share exchange; pre-closing holders diluted to 5.4%","bullets":["Exchange consideration: 4,083,779 common shares plus 2,692,633 Series B convertible preferred (convertible into 269,263,300 common).","Post-closing ownership: Sellers 79.8%, new Investor 5.9%, pre-closing Onconetix stockholders 5.4%.","Series B convertible preferred auto-converts on stockholder approval; cash settlement if approval not obtained by Jan 1, 2025.","Lock-up on Exchange Shares and Conversion Shares for 6 months after stockholder approval.","Post-approval board: 5 directors – 3 designated by Proteomedix, 2 by Onconetix."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-097738","json":"https://secwatch.observer/filing/0001213900-23-097738.json","markdown":"https://secwatch.observer/filing/0001213900-23-097738.md","text":"https://secwatch.observer/filing/0001213900-23-097738.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/0001213900-23-097738-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/ea190395-8k_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:16:24.414725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53b2b900a5","claim":"Christian Brühlmann was appointed as Chief Strategy Officer at Onconetix, Inc..","evidence_excerpt":"On December 15, 2023, Onconetix appointed Christian Brühlmann, 47, as Chief Strategy Officer of Onconetix, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/0001213900-23-097738-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Strategy Officer"}],"fact_type":"executive_change"},{"claim_id":"5869580371","claim":"Ralph Schiess was appointed as Chief Science Officer at Onconetix, Inc..","evidence_excerpt":"On December 15, 2023, Onconetix appointed Ralph Schiess, 45, as Chief Science Officer of Onconetix, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/0001213900-23-097738-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Science Officer"}],"fact_type":"executive_change"},{"claim_id":"3d75798d3a562c64667cf0ed546d01e9d406eb99","claim":"Onconetix, Inc.: Amended bylaws to reflect the name change to Onconetix, Inc (effective 2023-12-15).","evidence_excerpt":"On December 1, 2023, the Board approved the Name Change and an amendment to the Company’s bylaws to reflect the Name Change, effective as of the Closing Date on December 15, 2023. No other changes were made to the bylaws.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/0001213900-23-097738-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-12-15"}],"fact_type":"governance_change"},{"claim_id":"f80ca002cc448361bc232db67473db9dd7dfafe0","claim":"Onconetix, Inc.: Amended articles of incorporation to change company name from Blue Water Biotech, Inc. to Onconetix, Inc (effective 2023-12-15).","evidence_excerpt":"On December 15, 2023, Onconetix filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Delaware Secretary of State (the “ Amendment ”). The Amendment changed the name of Onconetix from “Blue Water Biotech, Inc.” to “Onconetix, Inc.,” effective immediately (the “ Name Change ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/0001213900-23-097738-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-12-15"}],"fact_type":"governance_change"},{"claim_id":"524ebb796b9c98c3e8824a9233fb38e5be6fb4ea","claim":"Onconetix, Inc. entered into Share Exchange Agreement with Proteomedix AG, the Sellers, and the Sellers’ Representative valued at $75,000,000 (effective 2023-12-15).","evidence_excerpt":"On December 15, 2023, Onconetix, Inc, a Delaware corporation f/k/a Blue Water Biotech, Inc. (“ Onconetix ” or the “ Buyer ”), entered into a Share Exchange Agreement (the “ Share Exchange Agreement ”), by and among (i) Onconetix, (ii) Proteomedix AG, a Swiss Company (“ Proteomedix ” or the “ Company ”), (iii) each of the holders of outstanding capital stock or Company Convertible Securities (other than Company Stock Options) named therein (collectively, the “ Sellers ”) and (iv) Thomas Meier, in the capacity as the representative of Sellers in accordance with the terms and conditions of the Share Exchange Agreement (the “ Sellers’ Representative ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023097738/0001213900-23-097738-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Proteomedix AG, the Sellers, and the Sellers’ Representative"},{"label":"Value","value":"$75,000,000"},{"label":"Effective","value":"2023-12-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}